MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 10, 2008; DOI: 10.1124/mol.107.043893


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043893v1
74/1/162    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galandrin, S.
Right arrow Articles by Bouvier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galandrin, S.
Right arrow Articles by Bouvier, M.


Received for publication December 7, 2007.
Revised March 27, 2008.
Accepted for publication April 2, 2008.

Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased MAPK Signaling through the {beta}1-Adrenergic Receptor

Segolene Galandrin 1, Genevieve Oligny-Longpre 1, Helene Bonin 1, Koji Ogawa 1, Celine Gales 1*, Michel Bouvier 1

1 Universite de Montreal

* Address correspondence to: E-mail: celine.gales{at}toulouse.inserm.fr

Abstract

In recent years, several studies have demonstrated that different ligands can have distinct efficacy profiles towards various signaling pathways through a unique receptor. For instance, {beta}1-adrenergic compounds that are inverse agonists toward the adenylyl cyclase (AC) can display agonist activity for the mitogenic-activated protein kinase (MAPK) pathway. Such phenomenon, often termed functional selectivity, has now been clearly established for many G protein-coupled receptors when considering distinct signaling output. However, the possibility that ligands could selectively engage distinct effectors to activate a single signaling output by promoting specific receptor conformations has not been extensively examined. Here, we took advantage of the fact that isoproterenol, bucindolol and propranolol (full, partial and inverse agonists for the AC pathway, respectively) all activate MAPK through the {beta}1-adrenergic receptor ({beta}1AR) to probe such conformational-biased signaling. Although the three compounds stimulated MAPK in a src-dependent manner, isoproterenol acted through both G{alpha}i{beta}{gamma} and G-protein independent pathways whereas bucindolol and propranolol promoted MAPK activation through the G protein-independent pathway only. The existence of such distinct signaling cascades linking {beta}1AR to MAPK activation was correlated with ligand-specific conformational rearrangements of receptor/G protein complexes measured by Bioluminescence Resonance Energy Transfer. Taken together, our data indicate that discrete local conformational changes can selectively promote the recruitment of distinct proximal signaling partners that can engage distinct signaling output and/or converge on the same one.


Key words: Adrenergic, Gi family, Gs family, Adenylyl cyclases, cAMP, Src and other nonreceptor tyrosine kinases, MAP Kinase, Fluorescence techniques, Structure/function/mechanism


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
N. Weitl and R. Seifert
Distinct Interactions of Human {beta}1- and {beta}2-Adrenoceptors with Isoproterenol, Epinephrine, Norepinephrine, and Dopamine
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 760 - 769.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers

Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics